TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06406777

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Contrast Lung Computed Tomography (CT) Scan
Description: CT scan of the lungs using contrast

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Lung Computed Tomography (CT) Scan
Description: CT scan of the lungs using contrast

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Lung Computed Tomography (CT) Scan
Description: CT scan of the lungs using contrast

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan
Description: MRI will be taken while subject is lying on their back breathing 100% oxygen.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan
Description: MRI will be taken while subject is lying on their back breathing 100% oxygen.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan
Description: MRI will be taken while subject is lying on their back breathing 100% oxygen.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 129Xe MRI scans
Description: MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 129Xe MRI scans
Description: MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 129Xe MRI scans
Description: MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
Study: NCT04926376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye90 Microspheres
Description: Y90 glass microspheres
Study: NCT06643845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical and non-medical treatments
Description: In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
Study: NCT04893226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Description: Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
Study: NCT06642818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocolized interview and prevention messages
Description: This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
Study: NCT06016907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Description: Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Description: Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
Study: NCT06588218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon
Description: 2.5 cups of whole fresh watermelon (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Belvita Breakfast Sandwich + 12 oz Water
Description: Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
Study: NCT06596525

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Whole Body Vibration Training (WBVTsh)
Description: During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated.
Study: NCT05218161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine alone
Description: All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine alone
Description: All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
Study: NCT06602063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery/chemotherapy
Description: secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery/chemotherapy
Description: secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at a fixed dose of 200 mg IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at a fixed dose of 200 mg IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
Study: NCT05324332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT06418763

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Baobab spread mixed with fermented brown seaweed
Description: 5-day intake period

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Baobab spread
Description: 5-day intake period
Study: NCT06639490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RUS GA
Description: he RUS GA (Endoscopic Imaging Treatment Planning Software, E04010.01(2)) is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the actual intra-abdominal surgical environment, allowing for the visualization of vascular structures and intra-abdominal organs during the surgical planning process and the operation. RUS GA utilizes preoperative CT images of the patient to segment organs and blood vessels and reconstructs them into a 3D model. Although there is no direct intervention with the patient, the surgeon uses RUS GA as a surgical navigation tool to simulate the surgery before performing the actual procedure.
Study: NCT05324332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
Study: NCT04175054

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload \>60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
Study: NCT06383598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/CT scan.
Study: NCT06655909

Intervention type: OTHER
Group type: OTHER
Intervention: consumption of maize porridge containing stable iron isotope
Description: consumption of maize porridge containing stable iron isotope

Intervention type: OTHER
Group type: OTHER
Intervention: consumption of maize porridge containing stable iron isotope
Description: consumption of maize porridge containing stable iron isotope
Study: NCT05392764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: once-daily oral empagliflozin 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching empagliflozin 10 mg
Study: NCT06032923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
Study: NCT06281171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkillTalk for Autistic Young Adults
Description: A Microskills video training library on communication skills for autistic young adults.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flyer Library
Description: A collection of existing online resources on relationship skills
Study: NCT06032923

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
Study: NCT06581926

Intervention type: OTHER
Intervention: Behavioral assessment
Description: nutrition knowledge reward-related eating body awareness

Intervention type: OTHER
Intervention: Behavioral assessment
Description: nutrition knowledge reward-related eating body awareness
Study: NCT06528496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DANYELZA
Description: DANYELZA is a humanized monoclonal antibody of the IgG1 subclass

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Yeast derived recombinant human Sargramostim (GM-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide is a structural analogue of cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is administered intravenously
Study: NCT05535582

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of clinical, laboratory and imaging profile
Description: Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.

Intervention type: DIAGNOSTIC_TEST
Intervention: Investigation of clinical, laboratory and imaging profile
Description: Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.
Study: NCT05504694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion.
Study: NCT06108492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2005
Description: In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Study: NCT06055556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Heart Transplantation
Description: Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freshly procured valve
Description: Fresh donor graft semilunar heart valve.
Study: NCT06120582

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 1
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 2
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 3
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 3
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.
Study: NCT06463171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.
Study: NCT06639490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Only standard treatment is performed.(Robot-assisted gastrectomy will be performed using without software RUS GA.)
Study: NCT06099821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Study: NCT06517836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iROP DL
Description: First, to evaluate the i-ROP DL system for autonomous ROP screening. To demonstrate the sensitivity and specificity of the i-ROP DL system on images obtained by technicians in the neonatal intensive care unit (NICU) setting to detect more than mild ROP (MTMROP), defined as type 2 or worse from the Early Treatment for ROP study) compared to an image-based reference standard diagnosis (RSD).
Study: NCT06586190

Intervention type: OTHER
Group type: OTHER
Intervention: Floor Pedal Bike with Guided Instructions for Home
Description: Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.
Study: NCT06665906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Behavioral Therapy (PainTrainer)
Description: Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Behavioral Therapy (PainTrainer)
Description: Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Cognitive Behavioral Therapy (PainTrainer)
Description: Self-guided program that contains 8 modules, lasting 30-40 minutes each and can be completed in 8 to 12 weeks. Each module teaches behavioral coping strategies for pain management and recommends practice exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Intervention
Description: At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Intervention
Description: At least six phone call visits, plus or minus 4, with patient navigator to coordinate care.
Study: NCT05184075

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hybrid coronary revascularization
Description: Patients will undergo endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the diagnostic coronarography. Furthermore, they will receive a percutaneous coronary intervention (PCI) within four weeks after the endo-CABG.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse hybrid coronary revascularization
Description: Patients will receive a percutaneous coronary intervention (PCI) within four weeks after the diagnostic coronarography. Furthermore, they will undergo the endoscopic coronary artery bypass grafting (endo-CABG) within four weeks after the PCI.
Study: NCT06671873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µCi [14C] HMPL-306
Description: D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose
Study: NCT06084013

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04926831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capmatinib
Description: 150 mg and 200 mg tablets for oral administration
Study: NCT05427994

Intervention type: OTHER
Intervention: National Eye Institute Visual Function Questionnaire
Description: National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
Study: NCT06517212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Patients will receive tirzepatide once weekly for up to 2 years.
Study: NCT05426096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory
Description: The BPA intervention will test the delivery of the insulin calculator (BPA) which automates the standard insulin dosing protocol guidelines through the electronic health record system.
Study: NCT06679075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using propolis and bioceramic putty
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and bioceramic putty as a dressing material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy using Propolis and MTA
Description: Full Pulpotomy for participants with mature adult molars diagnosed with irreversible pulpitis; using Propolis as a hemostatic agent and MTA as a dressing material
Study: NCT06610903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over